Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Venture Funding Deals, July 2016

This article was originally published in Start Up

Executive Summary

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.

You may also be interested in...



Vaccitech Will Seek Partners For Its Universal Flu Vaccine

Vaccitech's potential universal flu vaccine based on prime-boost technology is in early clinical trials in the UK, with partners likely to be sought for later-stage clinical studies; the company has just raised £20m in a Series A round from private investors that included Google's VC arm, GV, and Sequoia China.

Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval

Excitement around cell therapy has been building in recent years, but companies expect interest to accelerate after Gilead agreed to buy Kite for $11.9bn and Novartis won the first ever CAR-T approval.

Deals In Depth: October 2021

Six $1bn+ alliances were penned in October. Topping the list was a potential $3.6bn deal between Poseida Therapeutics and Takeda to utilize Poseida's genetic engineering platforms for the research and development of up to eight gene therapies. The collaboration will focus on non-viral in vivo gene therapy programs, including Poseida's preclinical hemophilia A program P-FVIII-101. Poseida will lead research activities up to candidate selection, after which Takeda will assume responsibility for further exclusive global development and commercialization.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel